Metabolic Comparison

5-Amino-1MQ vs CT-388

Comparison of 5-Amino-1MQ (Low evidence) and CT-388 (Moderate evidence).

Last updated: February 12, 2026

5-Amino-1MQ

Low Evidence
View full dossier

CT-388

Moderate Evidence
View full dossier

Overview

5-Amino-1MQ and CT-388 are both studied in the peptide research space.

5-Amino-1MQ: A small molecule NNMT inhibitor studied for metabolic effects in animal models.

CT-388: A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.

Evidence Comparison

Aspect5-Amino-1MQCT-388
Evidence LevelLowModerate
Human Studies16
Preclinical Studies112
Total Sources128

Key Differences

Aspect5-Amino-1MQCT-388
CategoryMetabolicMetabolic
Evidence StrengthLowModerate
Total Sources128
Human Studies16

Summary

  • 5-Amino-1MQ: Low evidence with 12 total sources (1 human)
  • CT-388: Moderate evidence with 8 total sources (6 human)

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.

Stay Updated on Peptide Comparisons

Get notified when we publish new comparison dossiers and evidence reviews.

No spam. Unsubscribe anytime.

Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.